designer491 New data on Johnson & Johnson's Talvey (talquetamab) maintained durable responses and high overall response rates in patients with multiple myeloma over the long term. In a phase 1/2 study, the overall survival rate was 67% at 24 months. At a median follow-up of 23.
4 months, patients in every two weeks dosed cohort showed a median duration of response of 17.5 months. For patients in the weekly arm with a median follow-up of 29.
8 months, showed a median DOR of 9.5 months. J&J said the results indicate that Talvey is efficacious when used before or after CAR-T therapy or bispecific antibody therapies in triple-class-exposed multiple myeloma patients.
More on Johnson & Johnson Johnson & Johnson: Market Will Regret The Overreaction Cancer victims seek court order to block J&J’s bankruptcy bid J&J in $700M settlement with states over marketing of talc products Johnson & Johnson (JNJ) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Johnson & Johnson (JNJ) Bernstein's 40th Annual Strategic Decisions Conference - (Transcript).